Synvista Therapeutics, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Synvista Therapeutics, Inc.
Tech Transfer Roundup: MD Anderson Tackles Cancer In Alliances With UroGen, Xencor, Obsidian
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
GSK Spending Spree Continues With Sosei Heptares Pact
Having just entered into drug discovery partnerships with Surface Oncology and Adrestia, GSK is paying £34m upfront to team up with Sosei Heptares to evaluate treatments for gastrointestinal immune disorders.
Data And Connected Insight Will Take Corin Beyond COVID-19
Corin has transformed from a niche UK hip resurfacing company into an innovative global player in orthopedics with a portfolio that includes robotics. UK branch managing director Paul Gibbons explained the group’s approach to business during COVID-19 and its culture of innovation.
Interview: Data And Connected Insight In Arthroplasty Will Take Corin Beyond COVID
Corin has transformed from a niche UK hip resurfacing company into an innovative global player in orthopedics with a portfolio that includes robotics. UK managing director Paul Gibbons explained the group’s approach to business during COVID-19, and its culture of innovation.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Alteon, Inc.